CYSE News Search

The FDA is set to approve SPRAVATOTM, an esketamine nasal spray that could help certain patients with severe depression. Dr. Drew Ramsey explains.

Dr. John Mann and colleagues followed 663 young adults who were at high risk for suicidal behavior because their parents had been diagnosed with mood disorders.

“When the child has not made academic progress despite accommodations, he or she can develop other challenges that negatively affect their functioning at home and at school,” says Dr. Meghan Tomb.

“Clearly, there has been renewed interest in TD, mainly prompted by the introduction of new drugs, which have marketing budgets associated with them,” writes Dr. Jeffrey Lieberman.